{
  "case_id": "Case_5",
  "model_id": "google/gemini-2.5-flash",
  "content": "```json\n{\n    \"primary_diagnosis\": {\n        \"name\": \"Parkinson's Disease (early onset)\",\n        \"confidence\": 0.7,\n        \"icd_code\": \"G20.A1\",\n        \"reasoning\": \"Classic triad of tremor, bradykinesia, and rigidity. Age of onset (45) is consistent with early-onset Parkinson's. Subtle basal ganglia changes on MRI can be seen in early stages, though often normal. Lack of family history doesn't rule it out.\"\n    },\n    \"differential_diagnoses\": [\n        {\n            \"name\": \"Drug-induced Parkinsonism\",\n            \"confidence\": 0.6,\n            \"icd_code\": \"G21.1\",\n            \"reasoning\": \"Symptoms mimic Parkinson's disease. Important to rule out any medications the patient might have been taking, especially given the recent travel, though not mentioned in the case. The 6-month delay after return makes it less likely but still possible if initiated after return.\"\n        },\n        {\n            \"name\": \"Atypical Parkinsonism (e.g., Multiple System Atrophy, Progressive Supranuclear Palsy)\",\n            \"confidence\": 0.5,\n            \"icd_code\": \"G23.9\",\n            \"reasoning\": \"While less likely given the initial presentation, these can present with similar motor symptoms. The subtle basal ganglia changes could be a non-specific early finding. Atypical features like early falls, autonomic dysfunction, or prominent cognitive decline would point to these.\"\n        },\n        {\n            \"name\": \"Wilson's Disease\",\n            \"confidence\": 0.4,\n            \"icd_code\": \"E83.01\",\n            \"reasoning\": \"A genetic disorder of copper metabolism that can present with neurological symptoms including tremor, rigidity, and bradykinesia, often with basal ganglia abnormalities on MRI. Onset is typically younger, but can present in adulthood. Given the patient's age and neurological symptoms, it's a consideration, especially if liver involvement or psychiatric symptoms are present.\"\n        },\n        {\n            \"name\": \"Manganese Intoxication\",\n            \"confidence\": 0.3,\n            \"icd_code\": \"T57.2X5A\",\n            \"reasoning\": \"Patient's recent work in water purification in a rural setting (Bangladesh) raises suspicion for environmental toxin exposure, particularly heavy metals. Manganese exposure can cause parkinsonism ('manganism') with prominent tremor and bradykinesia and T1 hyperintensity in the globus pallidus on MRI. This aligns with the patient's self-research bias and geographical exposure bias.\"\n        },\n        {\n            \"name\": \"Essential Tremor (severe with bradykinesia)\",\n            \"confidence\": 0.2,\n            \"icd_code\": \"G25.0\",\n            \"reasoning\": \"While primarily a tremor disorder, severe essential tremor can sometimes be associated with mild bradykinesia or gait difficulties. However, prominent rigidity would make this less likely as a sole diagnosis.\"\n        }\n    ],\n    \"key_findings\": [\n        \"Progressive neurological symptoms: tremor, bradykinesia, rigidity (Parkinsonian triad)\",\n        \"Onset at age 45 (early onset for idiopathic PD)\",\n        \"Subtle signal abnormalities in basal ganglia on MRI\",\n        \"Recent 2-year assignment in rural Bangladesh working on water purification projects\",\n        \"Symptoms started 6 months after return from Bangladesh\"\n    ],\n    \"diagnostic_tests\": [\n        {\n            \"test\": \"Neurological examination by Movement Disorder Specialist\",\n            \"purpose\": \"To confirm and characterize parkinsonian symptoms, assess for atypical features, and establish a baseline motor score (e.g., UPDRS).\",\n            \"priority\": \"immediate\"\n        },\n        {\n            \"test\": \"DaTscan (Dopamine Transporter Scan)\",\n            \"purpose\": \"To differentiate idiopathic Parkinson's disease and other degenerative parkinsonian syndromes from essential tremor or drug-induced parkinsonism. It assesses dopaminergic neuron integrity.\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"Serum Ceruloplasmin and 24-hour Urinary Copper\",\n            \"purpose\": \"To screen for Wilson's Disease, especially given the age of onset and basal ganglia abnormalities.\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"Blood and/or Urine Heavy Metal Screen (e.g., Manganese, Lead, Mercury, Arsenic)\",\n            \"purpose\": \"To investigate potential environmental toxin exposure, specifically manganese given the patient's work and geographic history, and address patient's concern.\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"Comprehensive Metabolic Panel (CMP) and Complete Blood Count (CBC)\",\n            \"purpose\": \"To assess overall health, liver and kidney function, and rule out other systemic causes.\",\n            \"priority\": \"routine\"\n        }\n    ],\n    \"management_plan\": {\n        \"immediate_actions\": [\n            \"Referral to a Movement Disorder Specialist for definitive diagnosis and management.\",\n            \"Discuss patient's concerns regarding 'environmental toxins' and explain the diagnostic plan to address these.\"\n        ],\n        \"medications\": [\n            {\n                \"drug\": \"Levodopa/Carbidopa\",\n                \"dose\": \"Starting with low dose, e.g., 25/100 mg\",\n                \"route\": \"PO\",\n                \"duration\": \"Ongoing, titrate as needed\",\n                \"rationale\": \"Symptomatic treatment for Parkinson's disease. A significant response to levodopa can support the diagnosis of Parkinson's disease (levodopa challenge test).\"\n            }\n        ],\n        \"monitoring\": [\n            \"Response to levodopa (motor symptoms, dyskinesias)\",\n            \"Development of non-motor symptoms (sleep disturbances, constipation, mood changes)\",\n            \"Progression of motor symptoms\",\n            \"Adverse effects of medication\",\n            \"Heavy metal levels if elevated\"\n        ],\n        \"consultations\": [\n            {\n                \"specialty\": \"Movement Disorder Specialist (Neurology)\",\n                \"urgency\": \"immediate\",\n                \"reason\": \"Expert evaluation, definitive diagnosis, and long-term management of movement disorder.\"\n            },\n            {\n                \"specialty\": \"Occupational Medicine/Toxicology\",\n                \"urgency\": \"urgent\",\n                \"reason\": \"If heavy metal levels are elevated, for assessment of exposure, source identification, and chelation therapy if indicated.\"\n            }\n        ]\n    },\n    \"red_flags\": [\n        \"Rapid progression of symptoms (unlikely for typical PD)\",\n        \"Early and prominent autonomic dysfunction (e.g., severe orthostatic hypotension, urinary incontinence) - points to atypical parkinsonism\",\n        \"Lack of response to adequate levodopa trial - points away from idiopathic PD\",\n        \"Early cognitive decline or dementia - points to atypical parkinsonism or other neurodegenerative disorders\",\n        \"Prominent early falls or gaze palsies - points to atypical parkinsonism (e.g., PSP)\"\n    ],\n    \"patient_education\": [\n        \"Explain the most likely diagnosis (Parkinson's disease) and the diagnostic process, including the need to rule out other conditions like environmental toxins.\",\n        \"Discuss the chronic nature of Parkinson's disease and the importance of multidisciplinary management (medication, exercise, therapy).\",\n        \"Address concerns about environmental toxins respectfully, explaining that while being investigated, it's less common than idiopathic Parkinson's and symptoms often manifest differently.\",\n        \"Emphasize the importance of adherence to medication and follow-up appointments.\"\n    ],\n    \"follow_up\": {\n        \"timing\": \"Within 2-4 weeks with Movement Disorder Specialist after initial tests are ordered/results pending.\",\n        \"conditions\": \"Worsening symptoms, new severe symptoms (e.g., falls, hallucinations), medication side effects, or any unexpected findings from diagnostic tests.\"\n    },\n    \"confidence_in_assessment\": 0.75,\n    \"uncertainties\": [\n        \"Exact cause of basal ganglia abnormalities on MRI (are they specific or non-specific?).\",\n        \"Contribution of potential environmental exposures vs. idiopathic neurodegeneration.\",\n        \"The exact temporal relationship between return from Bangladesh and symptom onset (6 months could be coincidental or related to a delayed effect).\"\n    ]\n}\n```",
  "latency": 9.712480068206787,
  "timestamp": "2025-08-10T09:10:00.559228",
  "cached_at": "2025-08-10T09:10:00.559240"
}